SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : SIBIA Neurosciences (SIBI)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Frank Stein who wrote (140)12/9/1997 8:33:00 PM
From: scaram(o)uche  Read Replies (1) of 579
 
Frank:

Agreed, from an efficacy stand.

However, Bayer doesn't touch a drug unless they consider the market to be north of $200 million. Therefore, in a second sense of the word "successful", the one that is relevant to my interest in SIBI, I'd say that there's reason for attention.

Johnson and Johnson, Pfizer, Eisai, Novartis, and Bayer are taking a different stance than yours.

Rick
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News